Amylyx Pharmaceuticals' stock soared 5.24% during intraday trading on Wednesday, following a bullish analyst update from H.C. Wainwright.
The firm's analyst, Andrew Fein, raised the price target on Amylyx to $34 from $28 and maintained a Buy rating on the shares. This positive rating action is seen as a key driver behind the significant upward movement in the stock price, reflecting increased analyst confidence in the company's prospects.